Intravenous antibiotic usage in high risk patients compared to FDA-approved usage.
D000667:Ampicillin / Q000009:adverse effects / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects; D002512:Cephalothin / Q000009:adverse effects / Q000627:therapeutic use; D004348:Drug Labeling; D004363:Drug Utilization; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008826:Microbial Sensitivity Tests / Q000592:standards; D009026:Mortality; D044469:Racial Groups; D012737:Sex Factors; D012959:Socioeconomic Factors; D013997:Time Factors; D014481:United States; D014486:United States Food and Drug Administration
D000900:Anti-Bacterial Agents; D000667:Ampicillin; D002512:Cephalothin